SEP 17, 2026 · JOURNAL ARTICLE
Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer
The Prostate
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant pros